Somatic allelic deletions and point mutations of the TP53 tumor suppressor gene, located at 17p13.1, are the most frequent genetic abnormalities in human cancers. 1 The wild-type p53 protein is normally undetectable by immunohistochemical analysis using anti-p53 monoclonal antibodies; however, the mutated p53 gene protein has a prolonged half-life allowing for detection of nuclear p53 protein by immunohistochemical analysis. 2,3 The detection of nuclear p53 protein expression has been associated with an adverse prognosis in certain human cancers, and efforts are underway to develop therapeutic agents that restore normal p53 function. 4,5 However, p53 protein expression is not always associated with TP53 mutation, 6-9 suggesting other mechanisms of p53 stabilization.
Somatic allelic deletions and point mutations of the TP53 tumor suppressor gene, located at 17p13.1, are the most frequent genetic abnormalities in human cancers. 1 The wild-type p53 protein is normally undetectable by immunohistochemical analysis using anti-p53 monoclonal antibodies; however, the mutated p53 gene protein has a prolonged half-life allowing for detection of nuclear p53 protein by immunohistochemical analysis. 2, 3 The detection of nuclear p53 protein expression has been associated with an adverse prognosis in certain human cancers, and efforts are underway to develop therapeutic agents that restore normal p53 function. 4, 5 However, p53 protein expression is not always associated with TP53 mutation, [6] [7] [8] [9] suggesting other mechanisms of p53 stabilization.
Hemizygous TP53 deletions are found in approximately 10% of patients with chronic lymphocytic leukemia (CLL) and are considered to be the most significant genetic abnormality associated with chemotherapy failure and poor survival. 10, 11 The prevalence of nuclear p53 expression detected by immunohistochemical analysis in CLL varies from 15% to 32% and predicts a poor prognosis, [12] [13] [14] but its relationship with TP53 gene deletion status and other CLL-associated genetic risk factors has not been established. Because immunohistochemical analysis is a routine and simple laboratory test that can readily detect p53 protein expression, we investigated a large, single-institution series of CLL cases and compared nuclear p53 protein expression with TP53 gene deletion status and other CLL-associated genetic factors.
was approved by the institutional research ethic board. A total of 110 patients diagnosed with CLL by World Health Organization classification criteria 15 were included in our study. There were 77 men and 33 women, with a median age of 58 years (range, 31-82 years). At the time of cytogenetic analysis, 51.8% of patients were previously untreated. The median follow-up from diagnosis was 62 months. Clinical and laboratory features are summarized in ❚Table 1❚.
Immunohistochemical Analysis
Serial 5-μm sections of B-5-fixed bone marrow biopsy specimens were cut and deparaffinized, and heat-induced antigen retrieval was performed with citrate buffer (pH 6.0) at 120°C for 10 minutes. The CLL cells were immunostained for CD20 at a 1:1,000 dilution or for p53 at a 1:200 dilution (DO-7, DAKO, Carpinteria, CA) using a biotin-streptavidinhorseradish peroxidase method. In sequential section slides, the corresponding CD20+ CLL cells were evaluated for p53 expression, and the percentages of the positive cells were estimated by 2 independent observers. Cases were considered positive if 10% or more of the nuclei of the CD20+ CLL cells were stained. A paraffin biopsy of an adenocarcinoma specimen with known positivity for p53 protein expression served as a positive immunohistochemical control sample. Nonimmune mouse serum was substituted for the primary antibody as a negative control sample.
Fluorescence In Situ Hybridization
Bone marrow aspirates archived on cytocentrifuged slides were hybridized for dual-color fluorescence in situ hybridization (FISH) combining SpectrumGreen-labeled CEP17 and SpectrumOrange-labeled 17p13.1 (TP53) probes (Vysis, Downers Grove, IL). At least 200 nuclei were scored to determine the prevalence of TP53 deletions. The positive cutoff level was established at 10%. 16 FISH was performed similarly for other CLL-associated genetic markers: 13q deletions, 11q deletions, and trisomy 12, as previously described. 16 
Statistical Analysis
Statistical analysis was used to compare the groups with and without nuclear p53 expression. The χ 2 and Fisher exact tests were used to analyze categorical data, and the Mann-Whitney U test was used to analyze continuous data. These tests were performed using SPSS, version 16.0 (SPSS, Chicago, IL). Two-sided P values less than .05 were considered to be statistically significant.
Results

Immunohistochemical Analysis
Of the 110 CLL cases, 14 (12.7%) were positive for nuclear p53 expression by immunohistochemical analysis. Among these positive cases, the prevalence of stained cells was 10% to 90% (median, 35%), and the staining intensity was often moderate to strong ❚Image 1❚. Among the negative cases, there were some with few stained cells (<2%), and most with no stained cells.
Fluorescence In Situ Hybridization
Interphase FISH revealed 15 cases that were positive for TP53 deletion, constituting 13.6% of the total cases. All positive cases showed hemizygous deletions; these deletions were found in 10% to 99% of cells (median, 66%; Image 1). Among most of the negative cases, the prevalence of TP53 deletion was less than 1% of cells. FISH results for other cytogenetic abnormalities are shown in Table 1 ; the incidence of each cytogenetic abnormality in our cohort is similar to the typical cytogenetic profile of CLL cases reported in the literature.
Comparing Nuclear p53 Expression With TP53 Deletion
All 14 cases with nuclear p53 expression were positive for TP53 deletion; there was only 1 case positive for TP53 deletion and negative for nuclear p53 expression (Table 1) . Therefore, using nuclear p53 expression to predict 17p deletion, the positive predictive value is 100% and the negative predictive value is 99.0%; the sensitivity is 93.3%, and the specificity is 100%. There was no association between p53 expression or TP53 deletion and other genetic abnormalities including 13q deletion, 11q deletion, and trisomy 12.
Discussion
Because hemizygous TP53 gene deletion is an independent prognostic factor in CLL and associated with an adverse outcome, 10,11 a robust assay could have clinical usefulness. We therefore investigated p53 immunohistochemical analysis in a large cohort of CLL cases and found a strong correlation between TP53 gene deletion and nuclear p53 protein expression. Thus, p53 immunohistochemical analysis in CLL may be regarded as a surrogate for TP53 deletion analysis in the routine clinical setting, particularly in centers where FISH is not available.
We identified p53 protein expression in 12.7% of the CLL cases, compatible with the previous report of 15% in a large series of CLL by immunohistochemical analysis using the same clone of anti-p53 monoclonal antibody (DO-7). 12 In addition, the same group showed a strong correlation between TP53 mutation and protein expression in their cohort, although FISH was not performed to assess the TP53 deletion status. Under normal conditions, p53 protein expression is not detectable by immunohistochemical analysis, but aberrant expression can be detected in the tumors, especially with p53 mutations. Although we did not perform mutational analysis for the TP53 gene, it is likely that mutations in the undeleted allele account for the majority of the nuclear p53+ cases because p53 mutations are strongly associated with hemizygous TP53 deletions in CLL. 11 A study of TP53 abnormalities and protein expression by flow cytometry in 28 cases of CLL found that flow cytometry produced a sensitivity of 87.5% and specificity of 80% in comparison with DNA sequencing analysis. However, sequencing may produce "false-negatives" because it only detects mutations present in more than 20% of cells in the sample, and 2 of the samples showed less than 20% deletion by FISH. 17 Using a different clone of anti-p53 antibody, PAB1801, that preferentially detects mutant p53, Lens et al 18 detected p53 expression by immunohistochemical analysis in 8% of 28 CLL cases, of which only 2 had TP53 mutations; however, they only examined exon 5-9 of the TP53 gene and may have missed the mutations outside this classic "hot spot." 8 Using immunohistochemical analysis with the DO-7 clone anti-p53 antibody on decalcified, paraffin-embedded marrow specimens, Giles et al 14 confirmed that the increased percentage of cells positive for p53 staining was associated with poor survival in CLL, but mutations or deletions of the TP53 gene were not examined in their cohort.
In addition to mutations, other mechanisms may stabilize nuclear p53 protein. One of the major factors contributing to p53 stabilization is via expression of p14ARF. 19 Alternatively, inhibition of MDM2-mediated degradation of p53 could block the degradation of p53 protein. 20 Further investigation of the mechanism of p53 dysregulation and functional consequences of p53 expression may provide the base for potential targeted therapy in this subset of aggressive CLLs.
Nuclear p53 expression, as detected by immunohistochemical analysis, is an accurate predictor of hemizygous TP53 deletion in CLL. Because immunohistochemical analysis is a widely available, rapid, robust, and inexpensive test, p53 immunostaining can readily be adopted in clinical practice to identify this subgroup of high-risk CLL patients for risk-stratified therapies.
